Table 3.
Summary of medical treatments for patients with gastric neuroendocrine tumors
Type I GNET | Type II GNET | Type III GNET | Type IV GNET | |
Resection | Simple surveillance, endoscopic polypectomy, surgical excision associated with or without surgical antrectomy, total gastrectomy | Simple surveillance, endoscopic polypectomy, surgical excision associated with or without surgical antrectomy, total gastrectomy | Radical surgery | Radical surgery |
Chemotherapy | Combination chemotherapy:Etoposide + cisplatin (CDDP)/carboplatin octreotide and pasireotide (SOM230);Somatosatin analogues; | |||
CDDP + CPT-11117Lu- and 90Y-labelled somatostatin analogues;Selective internal radiation therapy | ||||
Targeted radio therapy | ||||
Biological therapy | Interferon-α | |||
Molecular targeted therapy | Inhibition of angiogenesis or molecular targeting of growth factor receptors, including sunitinib and imatinib |
GNET: Gastric neuroendocrine tumor.